Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Alexander H. Staudacher"'
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-16 (2023)
Abstract Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade. Late detection of the disease means that in most cases the disease has advanced local
Externí odkaz:
https://doaj.org/article/9f82d15ef5b840f78e7d30dce87c0bbe
Publikováno v:
Cancer Reports, Vol 5, Iss 8, Pp n/a-n/a (2022)
Abstract Background Platinum‐based chemotherapy and radiotherapy are standard treatments for non‐small cell lung cancer, which is the commonest, most lethal cancer worldwide. As a marker of treatment‐induced cancer cell death, we have developed
Externí odkaz:
https://doaj.org/article/dab56df0e46c4bed96d39703a47c489f
Autor:
Alexander H. Staudacher, Vasilios Liapis, Nicole L. Wittwer, William Tieu, Hiu Chun Lam, Jeanette Leusen, Michael P. Brown
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 151, Iss , Pp 113090- (2022)
The Fc region of a monoclonal antibody (mAb) can play a crucial role in its biodistribution and therapeutic activity. The chimeric mAb, chDAB4 (APOMAB®), which binds to dead tumor cells after DNA-damaging anticancer treatment, has been studied pre-c
Externí odkaz:
https://doaj.org/article/1e87d14864f544fd89df4097ec0b1c0c
Autor:
Vasilios Liapis, William Tieu, Stacey E. Rudd, Paul S. Donnelly, Nicole L. Wittwer, Michael P. Brown, Alexander H. Staudacher
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 5, Iss 1, Pp 1-15 (2020)
Abstract Purpose The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in tumors but only becomes available for antibody binding in dead tumor cells. Henc
Externí odkaz:
https://doaj.org/article/2c10cc80c36c4e7986a8a5df99197a46
Autor:
Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, William Tieu, Tara L. Pukala, Alexander H. Staudacher, Eva Bezak
Publikováno v:
Cells, Vol 11, Iss 19, p 2983 (2022)
Mucin 1 is a transmembrane glycoprotein which overexpresses cancer-specific epitopes (MUC1-CE) on pancreatic ductal adenocarcinoma (PDAC) cells. As PDAC is a low survival and highly aggressive malignancy, developing radioimmunoconjugates capable of t
Externí odkaz:
https://doaj.org/article/c5b299e7a4b949ae817f2f2c43b6eb11
Autor:
Paul Reid, Alexander H. Staudacher, Loredana G. Marcu, Ian Olver, Leyla Moghaddasi, Michael P. Brown, Yanrui Li, Eva Bezak
Publikováno v:
Cells, Vol 9, Iss 8, p 1788 (2020)
Head and neck squamous cell carcinomas (HNSCC) resulting from human papillomavirus (HPV) are increasing in incidence but demonstrate significantly better treatment response than HNSCC from other causes such as tobacco and alcohol. This study sought t
Externí odkaz:
https://doaj.org/article/557b1e9e3e994238bd75cf00d085f12b
Autor:
Michael P. Brown, Patrick H. van Berkel, Timothy E. Adams, Olan Dolezal, David Chin, Jeff Jia Cheng Hou, Vasilios Liapis, Yanrui Li, Alexander H. Staudacher
Survival curves for mice treated with DAB4 or chDAB4 antibody drug conjugates.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e59557f7edc6ae92059079399d85d49
https://doi.org/10.1158/1535-7163.22507873
https://doi.org/10.1158/1535-7163.22507873
Autor:
Michael P. Brown, Patrick H. van Berkel, Timothy E. Adams, Olan Dolezal, David Chin, Jeff Jia Cheng Hou, Vasilios Liapis, Yanrui Li, Alexander H. Staudacher
Antibody drug conjugates used in the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9991bc907c8a3c1d7f42ea71d26171
https://doi.org/10.1158/1535-7163.22507864
https://doi.org/10.1158/1535-7163.22507864
Autor:
Michael P. Brown, Patrick H. van Berkel, Timothy E. Adams, Olan Dolezal, David Chin, Jeff Jia Cheng Hou, Vasilios Liapis, Yanrui Li, Alexander H. Staudacher
Chemotherapy increases cathepsin B expression and macrophages in tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e4c7d2b78ca469c9fa39500a8e4a60
https://doi.org/10.1158/1535-7163.22507879
https://doi.org/10.1158/1535-7163.22507879
Autor:
Michael P. Brown, Patrick H. van Berkel, Timothy E. Adams, Olan Dolezal, David Chin, Jeff Jia Cheng Hou, Vasilios Liapis, Yanrui Li, Alexander H. Staudacher
Antibody–drug conjugates (ADC) have revolutionized the field of cancer therapy. ADCs combine the high specificity of tumor-targeting monoclonal antibodies with potent cytotoxic drugs, which cannot be used alone because of their high toxicity. Till
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb099defac41dc19cd96a5c467208d71
https://doi.org/10.1158/1535-7163.c.6538810.v1
https://doi.org/10.1158/1535-7163.c.6538810.v1